Patents by Inventor Kathleen Ogilvie

Kathleen Ogilvie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11767520
    Abstract: Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 26, 2023
    Assignee: aTyr Pharma, Inc.
    Inventors: John D. Mendlein, Kathleen Ogilvie
  • Publication number: 20200377874
    Abstract: Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent.
    Type: Application
    Filed: April 19, 2018
    Publication date: December 3, 2020
    Inventors: John D. MENDLEIN, Kathleen OGILVIE
  • Publication number: 20180282402
    Abstract: Provided are antibodies that specifically bind to human histidyl-tRNA synthetase and related therapeutic compositions and methods for treating cancer, including as standalone therapies or in combination with cancer immunotherapies, for example, immune checkpoint modulators such as PD-1 inhibitors.
    Type: Application
    Filed: November 30, 2017
    Publication date: October 4, 2018
    Inventors: Ryan Andrew Adams, Luke Burman, Yeeting Chong, David King, John D. Mendlein, Leslie Nangle Greene, Kathleen Ogilvie, Kaitlyn Rauch